English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/38433
Share/Impact:
Statistics
logo share SHARE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Activity-Dependent Neuroprotective Protein (ADNP) Expression in the Amyloid Precursor Protein/Presenilin 1 Mouse Model of Alzheimer’s Disease

AuthorsFernández Montesinos, Rafael ; Torres, Manuel; Baglietto-Vargas, David; Gutiérrez, Antonia; Gozes, Illana; Vitorica, Javier ; Pozo, David
KeywordsAlzheimer’s disease
Neuropeptides
VIP
ADNP
Presenilins
Neurodegeneration
Biomarkers
Issue DateMay-2010
PublisherSpringer
CitationJournal of Molecular Neuroscience 41(1): 114-120 (2010)
AbstractA major determinant in the pathogenesis of Alzheimer’s disease (AD) is the deposition of β-amyloid (Aβ) peptides in specific areas of the central nervous system. Therefore, animal models of Alzheimer amyloidosis are excellent tools to identify candidates to facilitate drug screening and to understand the molecular pathology of AD. Activity-dependent neuroprotective protein (ADNP) plays an essential role in brain development, and NAP (NAPVSIPQ, generic name: davunetide)—a peptide derived from ADNP—is currently in clinical development for the treatment of neurodegenerative disorders. However, the link between ADNP expression and AD remains unexplored. To test whether ADNP is affected by the onset of AD and progression, we employed the PS1xAPP mouse model (PS1M146L × APP751SL transgenic mice) to analyze the mRNA expression of ADNP in the hippocampus and cerebellum in early and advanced stages of disease. Results showed that ADNP expression in 6-month-old PS1xAPP mice hippocampus was higher than in wild-type (WT) mice. ADNP was originally identified as a vasoactive intestinal peptide (VIP)-responsive gene taking part in the VIP-mediated neurotrophic pathway. Interestingly, the expression of VIP was not affected in the same experimental setting, suggesting that ADNP expression is a VIP-independent marker associated with AD. Moreover, in the cerebellum, a brain area not affected by Aβ deposition, ADNP mRNA expression in 6-month-old PS1xAPP and WT were not different. A similar extent of hippocampal ADNP expression was observed in 18-month-old WT and PS1xAPP mice, in contrast to the differential expression level at 6 months of age. However, hippocampal ADNP expression in both WT and PS1xAPP was increased with aging similar to VIP mRNA expression. Our findings support the hypothesis that ADNP expression is related to early or mild AD progression by a VIP-independent mechanism.
Description7 páginas, 2 figuras.
Publisher version (URL)http://dx.doi.org/10.1007/s12031-009-9300-x
URIhttp://hdl.handle.net/10261/38433
DOI10.1007/s12031-009-9300-x
ISSN0895-8696
Appears in Collections:(IBIS) Artículos
(CABIMER) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.